key: cord-0793665-sajss94x authors: Jin, Young-Hee; Min, Jung Sun; Jeon, Sangeun; Lee, Jihye; Kim, Seungtaek; Park, Tamina; Park, Daeui; Jang, Min Seong; Park, Chul Min; Song, Jong Hwan; Kim, Hyoung Rae; Kwon, Sunoh title: Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections date: 2020-12-16 journal: Phytomedicine DOI: 10.1016/j.phymed.2020.153440 sha: 03e8d802292808f2e594b06629bb72f13f91e3b5 doc_id: 793665 cord_uid: sajss94x Background: Highly effective novel treatments need to be developed to suppress emerging coronavirus (CoV) infections such as COVID-19. The RNA dependent RNA polymerase (RdRp) among the viral proteins is known as an effective antiviral target. Lycorine is a phenanthridine Amaryllidaceae alkaloid isolated from the bulbs of Lycoris radiata (L'Hér.) Herb. and has various pharmacological bioactivities including antiviral function. Purpose: We investigated the direct-inhibiting action of lycorine on CoV's RdRp, as potential treatment for emerging CoV infections. Methods: We examined the inhibitory effect of lycorine on MERS-CoV, SARS-CoV, and SARS-CoV-2 infections, and then quantitatively measured the inhibitory effect of lycorine on MERS-CoV RdRp activity using a cell-based reporter assay. Finally, we performed the docking simulation with lycorine and SARS-CoV-2 RdRp. Results: Lycorine efficiently inhibited these CoVs with IC(50) values of 2.123±0.053, 1.021±0.025, and 0.878±0.022 μM, respectively, comparable with anti-CoV effects of remdesivir. Lycorine directly inhibited MERS-CoV RdRp activity with an IC(50) of 1.406 ± 0.260 μM, compared with remdesivir's IC(50) value of 6.335 ± 0.731 μM. In addition, docking simulation showed that lycorine interacts with SARS-CoV-2 RdRp at the Asp623, Asn691, and Ser759 residues through hydrogen bonding, at which the binding affinities of lycorine (−6.2 kcal/mol) were higher than those of remdesivir (−4.7 kcal/mol). Conclusions: Lycorine is a potent non-nucleoside direct-acting antiviral against emerging coronavirus infections and acts by inhibiting viral RdRp activity; therefore, lycorine may be a candidate against the current COVID-19 pandemic. Background: Highly effective novel treatments need to be developed to suppress emerging 23 coronavirus (CoV) infections such as COVID-19. The RNA dependent RNA polymerase 24 (RdRp) among the viral proteins is known as an effective antiviral target. Lycorine is a 25 phenanthridine Amaryllidaceae alkaloid isolated from the bulbs of Lycoris radiata (L'Hér.) 26 Herb. and has various pharmacological bioactivities including antiviral function. simulation showed that lycorine interacts with SARS-CoV-2 RdRp at the Asp623, Asn691, 38 and Ser759 residues through hydrogen bonding, at which the binding affinities of lycorine 39 (−6.2 kcal/mol) were higher than those of remdesivir (−4.7 kcal/mol). 183 To examine the antiviral effect of lycorine (Fig. 1A) (Fig. 1B) . Our data showed 187 that IC 50 values were 2.123 ± 0.053 μM (Fig. 1C) , and the CC 50 values were >50 μM. These showed that lycorine did not induce the cytotoxic effect up to 10 μM ( Fig. 2A) . Then, we 211 measured NLuc and FLuc activities following lycorine treatment using the MERS-RdRp 212 activity assay. Data showed that lycorine treatment reduced the relative NLuc activity in a 213 dose-dependent manner, and that FLuc activity was maintained up to 3.6 μM. These data Fig. 1) . Therefore, these results 228 We also examined the antiviral effect of lycorine against the other emerging coronavirus CoV and SARS-CoV-2, respectively (Supplementary Table 1 ). We also confirmed the pocket site (Fig. 4B ). In addition, there were three hydrogen-bond interactions between 259 lycorine and the SARS-CoV-2 RdRp protein such as Asp623, Asn691, and Ser759 (Fig. 4B) . These suggested that these hydrogen bonds could increase binding affinity with the SARS- Coronavirus susceptibility to the antiviral 345 remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading 346 exoribonuclease Molecular dynamics simulation of zika virus NS5 RNA dependent RNA polymerase 349 with selected novel non-nucleoside inhibitors Multiple biological functions and pharmacological effects 351 of lycorine Antiviral activity of lycorine against Zika virus in vivo and in vitro Novel natural non-nucleoside inhibitors of 357 HIV-1 reverse transcriptase identified by shape-and structure-based virtual screening 358 techniques Identification 361 of novel compounds inhibiting chikungunya virus-induced cell death by high 362 throughput screening of a kinase inhibitor library Approved antiviral drugs over the past 50 years Antiviral (RNA) 367 activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related 368 substances The antiviral 370 compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus Compassionate use of remdesivir for patients with 374 severe Covid-19 Rapid identification of 376 inhibitors that interfere with poliovirus replication using a cell-based assay 379 Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved 380 drugs Coronavirus COVID-19 Global Cases by Johns Hopkins 382 CSSE Advances in the development 384 of nucleoside and nucleotide analogues for cancer and viral diseases Complete genome sequence of Middle East respiratory 388 23 syndrome coronavirus KOR/KNIH/002_05_2015, isolated in South Korea A cell-based 391 reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA 392 polymerase Identification of natural compounds with 395 antiviral activities against SARS-associated coronavirus Lycorine reduces mortality of 397 human enterovirus 71-infected mice by inhibiting virus replication A cell-based reporter assay for screening 399 inhibitors of MERS coronavirus RNA-dependent RNA polymerase activity Coronavirus as a possible cause of severe acute respiratory 403 syndrome Effect of alkaloids 405 isolated from Amaryllidaceae on herpes simplex virus Remdesivir and SARS-CoV-2: Structural 408 requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites High-throughput screening and identification of potent broad-spectrum 412 inhibitors of coronaviruses Discovery and synthesis of 418 a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside 419 (GS-5734) for the treatment of Ebola and emerging viruses AutoDock Vina: improving the speed and accuracy of docking 422 with a new scoring function, efficient optimization, and multithreading Coronavirus (COVID-19) Update: FDA issues 425 emergency use authorization for potential COVID-19 treatment Remdesivir in adults with severe COVID-19: a randomised, double-blind, 428 placebo-controlled, multicentre trial Evolution of HCV NS5B non-nucleoside inhibitors Structural basis for inhibition 434 of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Gemcitabine, lycorine and oxysophoridine 438 inhibit novel coronavirus (SARS-CoV-2) in cell culture funding acquisition. All data were generated in-house, and no paper mill was used. All 326 authors agree to be accountable for all aspects of work ensuring integrity and accuracy.